Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 181.31M P/E - EPS this Y 30.00% Ern Qtrly Grth -
Income -92.26M Forward P/E -2.42 EPS next Y 15.50% 50D Avg Chg 7.00%
Sales 3.25M PEG -0.21 EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.71 EPS next 5Y 23.30% 52W High Chg -72.00%
Recommedations 2.10 Quick Ratio 5.71 Shares Outstanding 113.56M 52W Low Chg 73.00%
Insider Own 20.32% ROA -23.98% Shares Float 85.09M Beta 2.22
Inst Own 60.75% ROE -42.24% Shares Shorted/Prior 13.07M/11.18M Price 1.96
Gross Margin - Profit Margin - Avg. Volume 771,237 Target Price 8.00
Oper. Margin -2,104.02% Earnings Date Nov 14 Volume 538,890 Change -3.92%
About Absci Corporation

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; and with AstraZeneca PLC for AI-driven drug discovery against an oncology target. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation News
11/21/24 Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
11/13/24 Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
11/12/24 Q3 2024 Absci Corp Earnings Call
11/12/24 Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
11/12/24 Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
11/07/24 Absci to Host R&D Day on December 12, 2024
10/31/24 Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
07:00 AM Absci to Participate in Upcoming Investor Conferences
10/15/24 Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
08/31/24 Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire
08/30/24 Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
08/16/24 Absci Second Quarter 2024 Earnings: Misses Expectations
08/14/24 Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
08/14/24 Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
08/12/24 ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
08/12/24 Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
07/31/24 Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now?
07/12/24 Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
07/10/24 Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
07/03/24 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ABSI Chatroom

User Image Woke_Mind_Virus Posted - 3 days ago

$ABSI Doesn't make any money, burns a lot of money, is pretty much a start up, and RFK...

User Image SenorFrog1 Posted - 3 days ago

$ABSI Might have to revisit this at 1.50

User Image Shlobby Posted - 4 days ago

$ABSI looks like spring setup if you are into that. Not my style but could be good trade $3 and up

User Image amrelsherbiny Posted - 5 days ago

@Bullbear1010101 $ABSI is a very good company with good management. Things take time and everything is possible

User Image Bullbear1010101 Posted - 5 days ago

$ABSI over 4 a few days ago! looks like $10 is never again unless miracle. no position but sad

User Image G1mmeTheTaco Posted - 6 days ago

$ABSI

User Image Bull0206 Posted - 1 week ago

$ABSI not understanding why this is dropping so hard, can any clarify who knows?

User Image cryptodhir Posted - 1 week ago

$ABSI abscess

User Image Woke_Mind_Virus Posted - 1 week ago

$ABSI

User Image traderXO Posted - 1 week ago

$ABSI loaded

User Image DrWodo Posted - 1 week ago

$ABSI frustrating

User Image Kernmantel Posted - 1 week ago

$ABSI Management should have warned that initial milestone payment for a new therapy is peanuts. It doesn't look like there is a growth strategy that doesn't include dilution in the next year or two. They need to reign in spending and focus on what will get the company the fastest to positive operational cash flows. Until then, Absci will be traded like any other pharma startup.

User Image SenorFrog1 Posted - 1 week ago

$ABSI Looking ugly..I’ll wait for 2.50 before I get back in

User Image IAmSpoli Posted - 1 week ago

$ABSI all charts broken. Good luck to all holders

User Image Woke_Mind_Virus Posted - 1 week ago

$ABSI ouch

User Image IAmSpoli Posted - 1 week ago

$ABSI need to see $4.80 to validate the higher highs and higher low thesis

User Image DrWodo Posted - 1 week ago

$ABSI hope we wave goodbye to the 4 handle forever

User Image TrendsetterTrading Posted - 1 week ago

$ABSI Massive pennant pattern formation looking to breakout. Needs volume to carry through the $4.50 overhead resistance mark and this could be a runner

User Image cryptodhir Posted - 1 week ago

$ABSI biologics.

User Image Stockboi_ Posted - 1 week ago

$ABSI earnings tomorrow by the way from what I understand

User Image Stockboi_ Posted - 1 week ago

Only holds $PITA $ABSI $TPST

User Image Stockboi_ Posted - 1 week ago

$ABSI

User Image Dgiggler Posted - 1 week ago

$ABSI pop at open looks likely, right before earnings in this market with this sentiment...

User Image burrow Posted - 2 weeks ago

$ABSI manipulation

User Image traderXO Posted - 2 weeks ago

$ABSI added

User Image ChessGM Posted - 2 weeks ago

$ABSI Heads up alert! Upcoming earnings on Tuesday, 11/12/2024 for $ABSI Neutral (5.0) Absci Corporation (NASDAQ: ABSI) is at a pivotal juncture as it prepares for its upcoming R&D Day and earnings report, which may significantly influence investor sentiment. The company is leveraging its generative AI capabilities in drug creation, recently collaborating with Twist Bioscience to design innovative therapeutic antibodies. This partnership could enhance Absci's competitive edge in the biotechnology sector, particularly in the rapidly evolving landscape of AI-driven drug development. Financially, Absci has been navigating a challenging market environment, reflected in its current P/E ratio, which stands at 25.5, indicating that investors are willing to pay a premium for its growth potential. However, concerns persist regarding its EPS growth, which has shown volatility, with analysts projecting a modest increase of 5% year-over-year. Revenue forecasts suggest a gradual uptick, with expected figures around $20 million for Q3 2024, reflecting a slight improvement compared to previous quarters, yet still trailing behind key industry peers, which exhibit more robust growth metrics. Looking ahead to the earnings report scheduled for November 12, 2024, market expectations are tempered. Analysts anticipate a mixed performance, with estimates suggesting a loss per share of $0.30, a figure that aligns with Absci’s ongoing investments in R&D and strategic alliances. Historically, Absci has faced challenges in meeting earnings expectations, which may weigh on its stock price if the upcoming results do not meet or exceed these consensus estimates. The upcoming conference call will be crucial for management to outline future growth strategies and address investor concerns, potentially impacting stock performance in the near term. Overall, while there is optimism surrounding Absci's innovative capabilities, the financial metrics and upcoming earnings performance suggest a cautious approach for investors. - Funds were net buyers of $ABSI during the previous reporting quarter. - Top 5 funds with large holdings in $ABSI: * Redmile Group LLC $25MM. New position. CGMFundRank: 73%, Fund Website: www.redmilegroup.com * ARK Investment Management LLC $17MM. New position. CGMFundRank: 61%, Fund Website: www.ark-invest.com * Casdin Capital LLC $3MM. New position. CGMFundRank: 59%, Fund Website: www.casdincapital.com * Boxer Capital LLC $2MM. New position. CGMFundRank: 72%, Fund Website: www.boxercap.com * Perceptive Advisors LLC $2MM. New position. CGMFundRank: 59%, Fund Website: www.perceptivelife.com - Last 10 days performance: -3% - Last 30 days performance: 5% - Last 90 days performance: 12% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal."

User Image Carl_K Posted - 2 weeks ago

$IPA $RXRX $ABSI $XBI One week from now. https://ir.ipatherapeutics.com/news/news-releases/news-details/2024/ImmunoPrecise-to-Host-TECHDAY-Cutting-Edge-AI-and-Biologics-Innovation/default.aspx

User Image burrow Posted - 2 weeks ago

$ABSI https://www.stocktitan.net/news/ABSI/absci-to-host-r-d-day-on-december-12-fc3ydwdtfrxc.html

User Image IAmSpoli Posted - 2 weeks ago

$ABSI nearly 10 months of consolidation.

User Image flam70 Posted - 3 weeks ago

$ABSI https://youtu.be/G191QnDPDNA?si=azhv7a5V20VEY1kR

Analyst Ratings
Guggenheim Buy Oct 2, 24
HC Wainwright & Co. Buy Aug 15, 24
Keybanc Overweight Jul 11, 24
Morgan Stanley Overweight Jul 3, 24
HC Wainwright & Co. Buy May 15, 24
Truist Securities Buy Mar 26, 24
HC Wainwright & Co. Buy Mar 22, 24
Scotiabank Sector Outperform Mar 14, 24
Truist Securities Buy Mar 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SCHIFFMAN GREGORY T Chief Financial Offi.. Chief Financial Officer Oct 20 Option 1.10 50,000 55,000 605,165 10/24/22
Korman Sarah General Counsel General Counsel Feb 09 Buy 7.96 4,250 33,830 14,250 02/10/22
McClain Sean President and Chief.. President and Chief Executive Jan 19 Buy 6.92 7,155 49,513 6,368,955 01/19/22
- - - Jul 28 Buy 16 1,875,000 30,000,000 8,031,094 07/28/21